Pathophysiological effects of human TNF-alpha-producing tumor xenografts in immunosuppressed mice

APMIS

Volumn 107, Issue 10, 1999, Pages 903-912

  Nagy, T ^a   Janossy T ^a   Vizler, C ^a   Bohus, K ^a   Joo F ^b   Vegh P ^a   Duda, Ernö ^a,b,c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c INSTITUTE OF BIOCHEMISTRY   (Hungary)

Author keywords

Anemia; Hypothermia; Immunosuppression; Liver pathology; TNF; Tumor graft; Xenograft

Indexed keywords

CALCIUM; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BODY TEMPERATURE; CACHEXIA; CALCIUM BLOOD LEVEL; CALCIUM MOBILIZATION; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER SIZE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FATALITY; FEMALE; HELA CELL; HUMAN CELL; IMMUNE DEFICIENCY; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEX DIFFERENCE; SYMPTOM; TUMOR ESCAPE; TUMOR XENOGRAFT; WEIGHT REDUCTION;

EID: 0032750030     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01490.x     Document Type: Article

References (25)

1. 1. Aggarwal BB, Natarajan K, Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 1996;7:93-124.
2. 2. Bauss F, Droge W, Männel DM. Tumor necrosis factor mediates endotoxic effects in mice. Infect Immun 1987;55:1622-5.
3. 3. Bendtzen K, Buschard K, Diamant M, Horn T, Svenson M. Possible role of IL-1, TNF-alpha and IL-6 in insulin-dependent diabetes mellitus and autoimmune thyroid disease. Lymphokine Res 1989;8:335-40.
4. 4. Beutler B. Tumor necrosis factors. The molecules and their emerging role in medicine. Raven Press, New York 1992.
5. 5. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Nat Acad Sci USA 1975;72:3666-70.
6. 6. Colbere-Garapin F, Horodniceanu F, Kourilsky K, Garapin AC. A new dominant hybrid selective marker for higher eukaryotic cells. J Mol Biol 1981;150:1-14.
7. 7. Derijk RH, Berkenbosch F, Hypothermia to endotoxin involves the cytokine tumor necrosis factor and the neuropeptide vasopressin in rats. Am J Physiol 1994;266:R9-R14.
8. 8. Duda E, Benkö S, Galiba E, Horváth I, Páli T, Joó F, Vígh L. TNF sensitivity of target cells is determined by the microviscosity of the plasma-membrane. Advances in Psychoneuroimmunology. New York: Plenum Press, 1994:181-90.
9. 9. Georgopoulos S, Plows D, Kollias G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 1996;46:86-97.
10. 10. Jánossy T, Vizler CS, Végh P, Duda E. The effect of TNF producing tumor grafts in mice. Eur Cytokine Netw 1992;3:195.
11. 11. Johnson RA, Boyce BF, Mundy GR, Roodman GD. Tumors producing human tumor necrosis factor induced hypercalcemia and osteoclastic bone resorption in nude mice. Endocrinology 1989;124:1424-7.
12. 12. Johnson RA, Waddelow TA, Caro J, Oliff A, Roodman GD. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989;74:130-8.
13. 13. Ksontini R, Colagiovanni DB, Josephs MD, Edwards CK 3rd, Tannahill CL, Solorzano CC, et al. Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis. J Immunol 1998;160:4082-9.
14. 14. Leist M, Gantner F, Bohlinger I, Germann PG, Tiegs G, Wendel A. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-alpha requires transcriptional arrest. J Immunol 1994; 153;1778-88.
15. 15. Maury CP, Teppo AM, Tumor necrosis factor in the scrum of patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:146-50.
16. 16. Moldawer LL, Marano MA, Wei H, Fong Y, Silen ML, Kuo G, et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989;3:1637-43.
17. 17. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987;50:555-63.
18. 18. Pócsik É, Duda E, Wallach D. Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells. J Inflamm 1995; 54:152-60.
19. 19. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. Spontaneous inflammatory demyelating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor alpha. Proc Nat Acad Sci USA 1995;92:11294-8.
20. 20. Roodman GD, Johnson RA, Clibon U. Tumor necrosis factor alpha and the anemia of chronic disease: effects of chronic exposure to TNF on erythropoiesis in vivo. Adv Exp Med Biol 1989; 271:185-96.
21. 21. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-72.
22. 22. Szelei J, Duda E. Entrapment of high-molecular-mass DNA molecules in liposomes for the genetic transformation of animal cells. Biochem J 1989;259:549-53.
23. 23. Tracey KJ, Morgello S, Koplin B, Fahey TJ 3rd, Fox J, Aledo A, et al. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. J Clin Invest 1990;86:2014-24.
24. 24. Tsutsui H, Matsui K, Kawada N, Hyodo Y, Okamura H, Higashino K, Nakanishi K. IL-18 accounts for both TNF-alpha-and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 1997; 159:3961-7.
25. 25. Warren DJ, Slordal L, Moore MA. Tumor-necrosis factor induces cell cycle arrest in multipotential hematopoietic stem cells: a possible radioprotective mechanism. Eur J Haematol 1990;45:158-63.